Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03585348 · ClinicalTrials.gov registry record
Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal
A clinical trial, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- 265,537
- Enrollment target
NCT03585348: Completed study, sponsored by Beth Israel Deaconess Medical Center.
NCT03585348 is a clinical trial that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 265,537 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03585348 has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- 265,537 participants
- Enrollment target
Study Summary
The use of neuromuscular blocking agents during surgery is associated with postoperative respiratory complications and increased risk of readmission to the hospital following ambulatory surgery. Understanding the clinical behavior of providers is essential in devising and assessing quality improvement projects since it is primarily individuals who determine the utilization of neuromuscular blocking drugs and reversal agents, not institutions. Therefore, the primary objective of this study is to determine the variability between individual anesthesia providers (attending physician, resident, nurse anesthetists) in the use of neuromuscular blocking drugs and reversal agents, using advanced statistical methods to adjust for differences in patient and procedure case mix. The investigators hypothesize that variance between individual anesthesia providers in the use of neuromuscular blocking drugs and reversal agents differs depending on provider type.
Primary Outcome
Neuromuscular blocking agent ED95 equivalent dose defined as the median effective dose required to achieve a 95% reduction in maximal twitch response from baseline.
Interventions
- OTHER Neuromuscular blocking agents
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265,537 participants |
| Start Date | 2018-06-29 |
| Est. Completion | 2021-03-31 |
What the finished NCT03585348 record still lists
NCT03585348 is an observational study that tracks outcomes without assigning an intervention. Its 265,537 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Neuromuscular blocking agents is the first listed.
NCT03585348 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03585348 about?
NCT03585348 is a clinical study titled "Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal". The use of neuromuscular blocking agents during surgery is associated with postoperative respiratory complications and increased risk of readmission to the hospital following ambulatory surgery. Understanding the clinical behavior of providers is essential in devising and assessing quality improveme...
What is the current status of trial NCT03585348?
This trial is currently completed. The enrollment target is 265,537 participants. The study started on 2018-06-29. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT03585348?
The interventions under investigation include: Neuromuscular blocking agents (OTHER).
Who is sponsoring clinical trial NCT03585348?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04735835 · 250,000 participants · NA
Personalized Responses to Dietary Composition Trial 3
- NCT02280733 · 300,000 participants
A Real-World Registry of Chronic Wounds and Ulcers
- NCT06694181 · 300,000 participants
Safe and Explainable AI
- NCT07314697 · 300,000 participants · NA
Arrival Time Implementation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI